BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Price Target Raised to $29.00

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) had its price objective increased by HC Wainwright from $27.00 to $29.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other research firms have also weighed in on BBOT. Stifel Nicolaus began coverage on BridgeBio Oncology Therapeutics in a report on Tuesday, February 10th. They set a “buy” rating and a $23.00 target price on the stock. Raymond James Financial raised BridgeBio Oncology Therapeutics to a “moderate buy” rating in a report on Friday, January 9th. Finally, Weiss Ratings initiated coverage on shares of BridgeBio Oncology Therapeutics in a research report on Wednesday, January 14th. They set a “sell (d+)” rating for the company. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, BridgeBio Oncology Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.00.

BridgeBio Oncology Therapeutics Price Performance

BridgeBio Oncology Therapeutics stock opened at $10.42 on Friday. The stock has a market cap of $833.91 million, a P/E ratio of -10.12 and a beta of 0.29. BridgeBio Oncology Therapeutics has a 52 week low of $8.50 and a 52 week high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.18.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of BridgeBio Oncology Therapeutics by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock worth $7,039,000 after purchasing an additional 20,385 shares during the period. Goldman Sachs Group Inc. bought a new stake in BridgeBio Oncology Therapeutics in the 4th quarter valued at $1,185,000. BIT Capital GmbH acquired a new position in BridgeBio Oncology Therapeutics in the 4th quarter valued at $313,000. CIBC Private Wealth Group LLC acquired a new position in BridgeBio Oncology Therapeutics in the 4th quarter valued at $63,000. Finally, Renaissance Technologies LLC bought a new position in BridgeBio Oncology Therapeutics during the 4th quarter worth $930,000. Institutional investors and hedge funds own 54.89% of the company’s stock.

Key BridgeBio Oncology Therapeutics News

Here are the key news stories impacting BridgeBio Oncology Therapeutics this week:

• Positive Sentiment: Publication of peer‑reviewed preclinical data for BBO‑11818 (panKRAS) in Cancer Discovery, highlighting potent activity against KRAS G12D/V/C, ON/OFF state inhibition, strong selectivity, and combination potential — adds scientific validation to BBOT’s lead KRAS program. Read More.
• Positive Sentiment: Early Phase 1 KONQUER‑101 clinical signals for BBO‑11818 (including a reported confirmed partial response in PDAC and encouraging anti‑tumor activity) support near‑term clinical upside and future data readouts expected H2 2026. Read More.
• Positive Sentiment: Quarterly results: BBOT reported EPS of ($0.49) vs. consensus ($0.67), beating estimates — a near‑term financial surprise that can reduce investor uncertainty around cash‑burn guidance and valuation assumptions. Read More.
• Positive Sentiment: HC Wainwright raised its price target to $29 and reiterated a Buy, signaling stronger sell‑side conviction and providing a high upside reference for investors. Read More.
• Neutral Sentiment: Corporate update/Q4 & FY‑2025 filing recap: BBOT summarized clinical progress across three RAS‑pathway programs (BBO‑8520, BBO‑11818, BBO‑10203) and reiterated combination strategies — useful context but largely already reflected in recent releases. Read More.
• Neutral Sentiment: Short‑interest data reported anomalies (0 shares / NaN change) for early March — appears to be a data glitch and unlikely to meaningfully explain price moves.
• Negative Sentiment: Key risk: important clinical and regulatory milestones (additional BBO‑11818 data and combination studies) are scheduled for H2 2026 — the multi‑quarter timeline sustains execution risk and valuation uncertainty until those readouts.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.